Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
Kuendgen
A
A
Fenk
R
R
Bruns
I
I
Dommach
M
M
Schutte
A
A
Engers
R
R
Hünerlitürkoglu
A
A
Haas
R
R
Kobbe
G
G
D000328:Adult; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012307:Risk Factors; D012422:Rupture, Spontaneous; D013161:Splenic Rupture / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim